Anti-CD20 CAR therapy - Orna Therapeutics
Latest Information Update: 20 May 2025
At a glance
- Originator Orna Therapeutics
- Class Antineoplastics; Cell therapies; Gene therapies; RNA
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Autoimmune disorders; Cancer
Most Recent Events
- 07 Dec 2024 Pharmacodynamics data from preclinical trials in Cancer presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
- 05 Nov 2024 Preclinical trials in Autoimmune disorders in USA (Parenteral) prior to November 2024
- 05 Nov 2024 Preclinical trials in Cancer in USA (Parenteral) prior to November 2024